Veradermics to present Phase 2/3 topline data for VDPHL01 oral minoxidil in male pattern hair loss at May 2026 congress

Veradermics, Incorporated

Veradermics, Incorporated

MANE

0.00
  • Veradermics set a May 30, 2026 poster at the World Congress for Hair Research to disclose topline Phase 2/3 Study 302 results for VDPHL01.
  • Results were previously shared in April 2026, with the upcoming presentation positioned as a fuller public readout.
  • Part A showed positive outcomes for VDPHL01, an extended-release oral minoxidil tablet, in more than 500 men with mild-to-moderate pattern hair loss.
  • The readout supports plans to advance VDPHL01 as a potential FDA-approved oral pill for pattern hair loss, a category without a new pill in decades.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260527702949) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.